Immunogenicity of repeated Sendai viral vector vaccination in macaques

Microbes and Infection

Volumn 14, Issue 13, 2012, Pages 1169-1176

  Kurihara, Kyoko ^a,b   Takahara, Yusuke ^a,b   Nomura, Takushi ^a,b   Ishii, Hiroshi ^a,b   Iwamoto, Nami ^a,b   Takahashi, Naofumi ^a,b   Inoue, Makoto ^c   Iida, Akihiro ^c   Hara, Hiroto ^c   Shu, Tsugumine ^c   Hasegawa, Mamoru ^c   Moriya, Chikaya ^b   Matano, Tetsuro ^a,b  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c DNAVEC Corporation   (Japan)

Author keywords

AIDS vaccine; CTL; SIV; Viral vector

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; HAPLOTYPE; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; SENDAI VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, GAG; GENETIC VECTORS; IMMUNIZATION, SECONDARY; MACACA MULATTA; RECOMBINANT FUSION PROTEINS; SAIDS VACCINES; SENDAI VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; TIME FACTORS; VACCINATION;

ANIMALIA; MACACA; MACACA MULATTA; SENDAI VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84868102082     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.07.016     Document Type: Article

References (35)

1. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing C., Ho D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 1994, 68:4650-4655.
2. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 1994, 68:6103-6110.
3. Matano T., Shibata R., Siemon C., Connors M., Lane H.C., Martin M.A. Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 1998, 72:164-169.
4. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189:991-998.
5. + lymphocytes. Science 1999, 28:857-860.
6. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature 2000, 406:793-798.
7. Goulder P.J., Watkins D.I. HIV and SIV CTL escape: implications for vaccine design. Nat. Rev. Immunol. 2004, 4:630-640.
8. McMichael A.J., Hanke T. HIV vaccines 1983-2003. Nat. Med. 2003, 9:874-880.
9. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., Montefiori D.C., Xu Y., Herndon J.G., Wyatt L.S., Candido M.A., Kozyr N.L., Earl P.L., Smith J.M., Ma H.L., Grimm B.D., Hulsey M.L., Miller J., McClure H.M., McNicholl J.M., Moss B., Robinson H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292:69-74.
10. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., Zhang Z.Q., Simon A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L., Schleif W.A., Zhu L., Freed D.C., Persaud N.V., Guan L., Punt K.S., Tang A., Chen M., Wilson K.A., Collins K.B., Heidecker G.J., Fernandez V.R., Perry H.C., Joyce J.G., Grimm K.M., Cook J.C., Keller P.M., Kresock D.S., Mach H., Troutman R.D., Isopi L.A., Williams D.M., Xu Z., Bohannon K.E., Volkin D.B., Montefiori D.C., Miura A., Krivulka G.R., Lifton M.A., Kuroda M.J., Schmitz J.E., Letvin N.L., Caulfield M.J., Bett A.J., Youil R., Kaslow D.C., Emini E.A. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002, 415:331-335.
11. Jin X., Ramanathan M., Barsoum S., Deschenes G.R., Ba L., Binley J., Schiller D., Bauer D.E., Chen D.C., Hurley A., Gebuhrer L., El Habib R., Caudrelier P., Klein M., Zhang L., Ho D.D., Markowitz M. Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J. Virol. 2002, 76:2206-2216.
12. Hansen S.G., Vieville C., Whizin N., Coyne-Johnson L., Siess D.C., Drummond D.D., Legasse A.W., Axthelm M.K., Oswald K., Trubey C.M., Piatak M.J., Lifson J.D., Nelson J.A., Jarvis M.A., Picker L.J. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 2009, 15:293-299.
13. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., Abbink P., Coffey R.T., Grandpre L.E., Seaman M.S., Landucci G., Forthal D.N., Montefiori D.C., Carville A., Mansfield K.G., Havenga M.J., Pau M.G., Goudsmit J., Barouch D.H. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457:87-91.
14. Excler J.L., Parks C.L., Ackland J., Rees H., Gust I.D., Koff W.C. Replicating viral vectors as HIV vaccines: summary report from the IAVI sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals 2010, 38:511-521.
15. Berkley S.F., Koff W.C. Scientific and policy challenges to development of an AIDS vaccine. Lancet 2007, 370:94-101.
16. Kato A., Sakai Y., Shioda T., Kondo T., Nakanishi M., Nagai Y. Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells 1996, 1:569-579.
17. Kano M., Matano T., Kato A., Nakamura H., Takeda A., Suzaki Y., Ami Y., Terao K., Nagai Y. Primary replication of a recombinant Sendai virus vector in macaques. J. Gen. Virol. 2002, 83:1377-1386.
18. Li H.O., Zhu Y.F., Asakawa M., Kuma H., Hirata T., Ueda Y., Lee Y.S., Fukumura M., Iida A., Kato A., Nagai Y., Hasegawa M. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. 2000, 74:6564-6569.
19. Matano T., Kobayashi M., Igarashi H., Takeda A., Nakamura H., Kano M., Sugimoto C., Mori K., Iida A., Hirata T., Hasegawa M., Yuasa T., Miyazawa M., Takahashi Y., Yasunami M., Kimura A., O'Connor D.H., Watkins D.I., Nagai Y. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 2004, 199:1709-1718.
20. Moriya C., Horiba S., Kurihara K., Kamada T., Takahara Y., Inoue M., Iida A., Hara H., Shu T., Hasegawa M., Matano T. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies. Vaccine 2011, 29:8557-8563.
21. Kato M., Igarashi H., Takeda A., Sasaki Y., Nakamura H., Kano M., Sata T., Iida A., Hasegawa M., Horie S., Higashihara E., Nagai Y., Matano T. Induction of Gag-specific T-cell responses by therapeutic immunization with a Gag-expressing Sendai virus vector in macaques chronically infected with simian-human immunodeficiency virus. Vaccine 2005, 23:3166-3173.
22. Naruse T.K., Chen Z., Yanagida R., Yamashita T., Saito Y., Mori K., Akari H., Yasutomi Y., Miyazawa M., Matano T., Kimura A. Diversity of MHC class I genes in Burmese-origin rhesus macaques. Immunogenetics 2010, 62:601-611.
23. Kawada M., Igarashi H., Takeda A., Tsukamoto T., Yamamoto H., Dohki S., Takiguchi M., Matano T. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques. J. Virol. 2006, 80:1949-1958.
24. Nomura T., Yamamoto H., Shiino T., Takahashi N., Nakane T., Iwamoto N., Ishii H., Tsukamoto T., Kawada M., Matsuoka S., Takeda A., Terahara K., Tsunetsugu-Yokota Y., Iwata-Yoshikawa N., Hasegawa H., Sata T., Naruse T.K., Kimura A., Matano T. Association of major histocompatibility complex class I haplotypes with disease progression after simian immunodeficiency virus challenge in Burmese rhesus macaques. J. Virol. 2012, 86:6481-6490.
25. Kawada M., Tsukamoto T., Yamamoto H., Iwamoto N., Kurihara K., Takeda A., Moriya C., Takeuchi H., Akari H., Matano T. Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J. Virol. 2008, 82:10199-10206.
26. + T-Cell help on control of a simian immunodeficiency virus challenge in rhesus macaques. J. Virol. 2009, 83:9339-9346.
27. + cell responses in vaccine-based simian immunodeficiency virus controllers. AIDS 2010, 24:2777-2787.
28. Moriya C., Igarashi H., Takeda A., Tsukamoto T., Kawada M., Yamamoto H., Inoue M., Iida A., Shu T., Hasegawa M., Nagai Y., Matano T. Abrogation of AIDS vaccine-induced cytotoxic T lymphocyte efficacy in vivo due to a change in viral epitope flanking sequences. Microbes. Infect. 2008, 10:285-292.
29. Kestler H.W., Ringler D.J., Mori K., Panicali D.L., Sehgal P.K., Daniel M.D., Desrosiers R.C. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65:651-662.
30. Yoshizaki M., Hironaka T., Iwasaki H., Ban H., Tokusumi Y., Iida A., Nagai Y., Hasegawa M., Inoue M. Naked Sendai virus vector lacking all of the envelope-related genes: reduced cytopathogenicity and immunogenicity. J. Gene. Med. 2006, 8:1151-1159.
31. Moriya C., Horiba S., Inoue M., Iida A., Hara H., Shu T., Hasegawa M., Matano T. Antigen-specific T-cell induction by vaccination with a recombinant Sendai virus vector even in the presence of vector-specific neutralizing antibodies in rhesus macaques. Biochem. Biophys. Res. Commun. 2008, 371:850-854.
32. Takeda A., Igarashi H., Kawada M., Tsukamoto T., Yamamoto H., Inoue M., Iida A., Shu T., Hasegawa M., Matano T. Evaluation of the immunogenicity of replication-competent V-knocked-out and replication-defective F-deleted Sendai virus vector-based vaccines in macaques. Vaccine 2008, 26:6839-6843.
33. Sumida S.M., Truitt D.M., Lemckert A.A.C., Vogels R., Custers J.H.H.V., Addo M.M., Lockman S., Peter T., Peyerl F.W., Kishko M.G., Jackson S.S., Gorgone D.A., Lifton M.A., Essex M., Walker B.D., Goudsmit J., Havenga M.J.E., Barouch D.H. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 2005, 174:7179-7185.
34. Catanzaro A.T., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., Gu L., Martin J.E., Novik L., Chakrabarti B.K., Butman B.T., Gall J.G., King C.R., Andrews C.A., Sheets R., Gomez P.L., Mascola J.R., Nabel G.J., Graham B.S. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 2006, 194:1638-1649.
35. Priddy F.H., Brown D., Kublin J., Monahan K., Wright D.P., Lalezari J., Santiago S., Marmor M., Lally M., Novak R.M., Brown S.J., Kulkarni P., Dubey S.A., Kierstead L.S., Casimiro D.R., Mogg R., Dinubile M.J., Shiver J.W., Leavitt R.Y., Robertson M.N., Mehrotra D.V., Quirk E. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 2008, 46:1769-1781.